Eisai/Biogen Say Alzheimer’s Candidate BAN2401 Delivered Positive Data at 18 Month Analysis

Eisai and Biogen said on July 5 that their Alzheimer’s disease (AD) candidate BAN2401 achieved a statistically significant slowing of disease progression and reduction of amyloid accumulation in the brain at the final analysis of a PII study at 18...read more